INTRODUCTION
============

Enterococci have emerged as major nosocomial pathogens that cause healthcare-associated infections as well as prolonged colonization in patients with comorbidities \[[@B1]\]. They are the third most common cause of bacteremia at the Catholic Blood and Marrow Transplantation (BMT) Center of Seoul St. Mary\'s Hospital, Seoul, Korea. Additionally, vancomycin-resistant *enterococci* (VRE) account for 28% of all enterococcal bacteremia in hematologic \[MH\] patients \[[@B2][@B3]\] compared with approximately 15% in non-MH patients in this hospital. Recent history of antibiotic use, especially fluoroquinolone or broad-spectrum beta-lactam agents, has been reported as the major risk factor for VRE infection \[[@B4][@B5]\]. Fluoroquinolone is commonly used as a prophylaxis during chemotherapy or stem cell transplantation (SCT) for MH patients.

One of the clinical concerns regarding enterococcal infection stems from its intrinsic resistance to broad-spectrum antibiotics, which can lead to a delay in appropriate antimicrobial therapy. Other important issues regarding VRE include the poor outcomes of infected patients and the possibility of horizontal transfer of vancomycin resistance \[[@B6][@B7]\]. Vancomycin-resistant *Enterococcus faecium* (VREfm) has recently been recognized as an endemic nosocomial pathogen in many hospitals worldwide \[[@B8][@B9]\].

As only a limited number of reports have investigated the molecular characteristics of *E. faecium* bacteremic isolates according to different host factors and antibiotic resistance, we compared the molecular characteristics of (1) vancomycin-susceptible *E. faecium* (VSEfm) and VREfm bacteremic isolates in general, (2) VSEfm from MH and non-MH patients, and (3) VREfm from MH and non-MH patients.

METHODS
=======

1. Bacterial isolates
---------------------

A total of 120 *E. faecium* bacteremic isolates were collected from January 2012 to December 2013 at Seoul St. Mary\'s Hospital. An equal number of VSEfm and VREfm isolates were consecutively obtained from adult MH and non-MH patients: 42 VSEfm and 42 VREfm from MH patients, and 18 VSEfm and 18 VREfm from non-MH patients. For this study, *E. faecium* bacteremia was defined as isolation of *E. faecium* species from one or more blood cultures using an automated blood culture system (Bactec FX, Becton Dickinson, Sparks, MD, USA) \[[@B10]\]. If *E. faecium* was repeatedly isolated from a single patient, only the first bacteremic isolate was used for molecular analysis. This study was approved by the Institutional Review Board (IRB) of Seoul St. Mary\'s Hospital at the Catholic University of Korea with an informed consent waiver because the study utilized previously collected bacterial isolates without any individualized patient information (IRB number: KC14SISI0696).

2. Antimicrobial susceptibility test
------------------------------------

The susceptibility to ampicillin, vancomycin, teicoplanin, tigecycline, linezolid, and quinupristin/dalfopristin and high-level resistance to gentamicin (HLGR) and streptomycin were evaluated using the Vitek AST-P600 and Vitek II systems (bioMérieux, Hazelwood, MO, USA), according to the CLSI guidelines \[[@B11]\]. The presence of *vanA* and *vanB* was determined using the Seeplex VRE ACE Detection kit (Seegene, Seoul, Korea).

3. Molecular typing, plasmid analysis, and virulence gene profiling
-------------------------------------------------------------------

Multilocus sequence typing (MLST) of *E. faecium* isolates was conducted as previously described, based on seven housekeeping genes (*adk*, *atpA*, *ddl*, *gdh*, *gyd*, *purk*, and *pstS*) \[[@B12]\]. Different sequences at a given locus were assigned an allele number based on the *E. faecium* MLST database (<http://efaecium.mlst.net>), and each unique combination of alleles (the allelic profile) was designated as an ST.

Eight enterococcal plasmids (pIP501, pRE25, PEF1071, pRI, pRUM, pEF418, pMG1, and pLG1) were sequenced by PCR-based typing as previously described \[[@B7][@B13]\]. The presence of the virulence genes *hyl* (glucoside hydrolase), *cylA* (cytolysin), *gelE* (gelatinase), *esp* (enterococcal surface protein), *acm* (adhesin of collagen from *E. faecium*), *scm* (second collagen adhesion of *E. faecium*, fms10), *sgrA* (serine-glutamate repeat containing protein A), *ecbA* (*E. faecium* collagen binding protein, *fms18*), *asa1* and *agg* (aggregation substances), *pilA* and *pilB* (pilus-like structures), *fms11*, *fms14*, and *fms15* (*E. faecium* surface proteins) was evaluated by PCR as previously described \[[@B13][@B14]\].

4. Structural analysis of Tn*1546* elements
-------------------------------------------

For the structural analysis of Tn*1546* elements, overlapping internal regions of Tn*1546* were amplified using PCR as previously described \[[@B15]\]. Representative isolates in each ST exhibiting PCR fragments longer or shorter than those of the BM4147 prototype *vanA* gene cluster 7 were purified using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). Purified PCR products were directly sequenced using an ABI Prism 3700 DNA Sequencer (Applied Biosystems, Foster City, CA, USA). The acquired nucleotide sequences were analyzed using the BLASTN tool from the NCBI database (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

5. Statistical analysis
-----------------------

Statistical analysis was performed using SPSS software version 24.0 (SPSS Korea, Seoul, Korea). Chi-square analysis and Student\'s t-test were used to compare categorical variables and continuous variables, respectively. If any of the cells of a contingency table were below five, Fisher\'s exact test was used to compare categorical variables. Mann-Whitney U test was used to compare nonparametric continuous variables. A two-tailed *P* value≤0.05 was considered statistically significant.

RESULTS
=======

1. Antimicrobial resistance
---------------------------

The results of resistance to eight antibiotics are listed in [Table 1](#T1){ref-type="table"}. Ampicillin resistance was observed in 86.7% (52 of 60) of VSEfm isolates and was higher in VSEfm from MH patients than in VSEfm from non-MH patients (97.6% vs 61.1%, *P*=0.001). HLGR was also higher in VSEfm from MH patients than in VSEfm from non-MH patients (71.4% vs 38.9%, *P*=0.023). The resistance rate for the other antibiotics was similar in *E. faecium* isolates from MH and non-MH patients. All 60 VREfm isolates carried the *vanA* gene.

2. MLST
-------

The predominant ST among the 120 *E. faecium* isolates tested was ST17 (36.7%, 44 of 120), followed by ST230 (19.2%, 23 of 120), ST192 (14.2%, 17 of 120), ST78 (6.7%, 8 of 120), and ST262 (4.2%, 5 of 120). These five major clones represented 80.8% (97 of 120) of *E. faecium* bacteremic isolates. [Table 2](#T2){ref-type="table"} shows the MLST results segregated by vancomycin resistance and a comparison between MH and non-MH patients.

No significant differences were observed in the overall distribution of STs between VSEfm and VREfm. However, the ST distribution of VSEfm and VREfm could be distinguished according to the patient group. Among the 42 VSEfm isolates from MH patients (VSEfm MH), ST17 was predominant (42.9%), followed by ST192 and ST230 (14.3%) ([Fig. 1A](#F1){ref-type="fig"}). In comparison, no predominant clone was observed among the 18 VSEfm isolated from non-MH patients (VSEfm non-MH); identified STs included ST17 (22.2%), ST192, and ST812 (16.7%) ([Fig. 1B](#F1){ref-type="fig"}). ST230 was the most common (33.3%) ST among the VREfm isolates from MH patients (VREfm MH), followed by ST17 (26.2%) ([Fig. 1C](#F1){ref-type="fig"}), while ST17 was predominant (61.1%) in VREfm isolates from non-MH patients (VREfm non-MH) ([Fig. 1D](#F1){ref-type="fig"}). A population snapshot obtained using eBURST analysis (<http://eburst.mlst.net>) is shown in [Fig. 2](#F2){ref-type="fig"}.

3. Prevalence of the virulence genes and plasmids
-------------------------------------------------

Of the 15 virulence genes tested, several were rarely identified or not identified in the 120 *E. faecium* isolates; these included *cylA* (n=1), *gelE* (n=0), *asa1* (n=1), and *agg* (n=0). In contrast, *acm*, which encodes a factor related to adhesion of collagen, was detected in all bacteremic isolates (n=120). The distribution of virulence factors differed between VSEfm and VREfm; *hyl* (91.7% vs 76.7%, *P*=0.024) and *sgrA* (100% vs 85.0%, *P*=0.003) were more frequent in VREfm than in VSEfm ([Table 3](#T3){ref-type="table"}). In addition, *hyl* (85.7% vs 55.6%, *P*=0.011), *esp* (83.3% vs 55.6%, *P*=0.023), and *sgrA* (92.9% vs 66.7%, *P*=0.016) were more frequent in VSEfm MH than in VSEfm non-MH.

Furthermore, we compared the virulence factors correlated with resistance to antibiotics other than vancomycin. *Hyl* (90.2%, vs 0%, *P*\<0.001), *esp* (86.6% vs 0%, *P*\<0.001), *sgrA* (97.3% vs 25.0%, *P*\<0.001), *ecbA* (67.9% vs 12.5%, *P*=0.003), *scm* (78.6% vs 37.5%, *P*=0.020), *pilB* (71.4% vs 12.5%, *P*=0.002), and *fms15* (78.6% vs 12.5%, *P*\<0.001) were more frequently detected in ampicillin-resistant *E. faecium* than in ampicillin-susceptible *E. faecium*. Additionally, *hyl* (93.2% vs 68.9%, *P*\<0.001), *esp* (87.8% vs 68.9%, *P*=0.011), *sgr* (98.6% vs 82.2%, *P*=0.002), *ecbA* (71.6% vs 51.1%, *P*=0.024), and *pilB* (74.3% vs 55.6%, *P*=0.034) were more frequent in *E. faecium* with HLGR than in *E. faecium* without HLGR.

Similar to the virulence factors, the plasmids harboring *rep* genes exhibited different patterns according to antimicrobial resistance and/or patient group. pEF1071 was more frequent in VREfm than in VSEfm (90.0% vs 70.0%, *P*=0.006; [Table 3](#T3){ref-type="table"}). In addition, the prevalence of pEF1071 was higher among ampicillin-resistant *E. faecium* isolates (85.7%), whereas it was not found in any of the ampicillin-susceptible *E. faecium* isolates. Furthermore, *E. faecium* harboring pEF1071 more frequently harbored *hyl* (93.8% vs 45.8%, *P*\<0.001), *esp* (91.7% vs 37.5%, *P*\<0.001), *sgrA* (99.0% vs 66.7%, *P*\<0.001), *ecbA* (71.9% vs 33.3%, *P*\<0.001), *pilB* (76.0% vs 33.3%, *P*\<0.001), and *fms15* (80.2% vs 50.0%, *P*=0.002).

pLG1 was more frequent in ampicillin-resistant *E. faecium* isolates than in ampicillin-susceptible isolates (81.3% vs 37.5%, *P*=0.012). pLG1 was also more prevalent in both VSEfm (81.0% vs 55.6%, *P*=0.041) and VREfm (90.5% vs 66.7%, *P*=0.023) from MH patients than those from non-MH patients. This prevalence was significantly related to the presence of *esp*, *sgrA*, *pilB*, and *fms15*; *E. faecium* harboring pLG1 also harbored *esp* (85.1% vs 65.4%, *P*=0.024), *sgrA* (95.7 vs 80.8%, *P*=0.022), *pilB* (73.4 vs 46.2%, *P*=0.009), and *fms15* (79.8% vs 53.8%, *P*=0.007) more frequently than did *E. faecium* without pLG1.

Taken together, the common virulence factors esp and *sgrA* were more prevalent in *E. faecium* isolates from MH patients, ampicillin-resistant isolates, and isolates harboring pEF1071 or pLG1. In addition, of the seven virulence factors prevalent in ampicillin-resistant isolates, six were also more prevalent among isolates harboring pEF1071, as pEF1071 was found only in ampicillin-resistant isolates.

4. Structural analysis of Tn*1546*
----------------------------------

Result of the structural analysis of the main Tn*1546* type for VREfm is presented in [Table 2](#T2){ref-type="table"} and [Fig. 3](#F3){ref-type="fig"}. None of the isolates harbored the prototype Tn*1546*. The isolates were classified into five (I--V) main Tn types according to the presence of *orf1* and insertion of IS*1542* and/or IS*1216*. *orf1* was detected in most (54 of 60, 90%) of the isolates. Insertion of IS*1542* in the *orf2-vanR* region was observed in 85.7% (36 of 42) of VREfm MH and 94.4% (17 of 18) of VREfm non-MH, respectively. Insertion of IS*1216V* in the *vanX*--*vanY* intergenic region was found in 57.1% (24 of 42) of VREfm MH and 72.2% (13 of 18) of VREfm non-MH, and most of these isolates also harbored an IS1542 insertion. In other words, 88.3% (53 of 60) and 61.7% (37 of 60) of all the VREfm isolates had IS*1542* and IS*1216V* insertions, respectively. Type II was the most common, accounting for 50% (30 of 60) of all VREfm isolates. Tn types exhibited a variable pattern of distribution, which was difficult to characterize according to ST or host specificity.

DISCUSSION
==========

In this study, we compared the molecular characteristics of *E. faecium* bacteremic isolates according to host factors (MH vs non-MH patients). Seoul St. Mary\'s Hospital is a 1,300-bed, university-affiliated, tertiary care center in Seoul, South Korea; approximately 230 beds were allocated to MH patients. The Catholic BMT Center performs over 500 SCTs annually. Oral ciprofloxacin (500 mg twice daily) was used as a routine prophylaxis during chemotherapy or SCT throughout the study period. The initial empirical treatment for neutropenic fever in patients with hematological malignancy includes anti-pseudomonal cephalosporin (ceftazidime or cefepime) and/or an aminoglycoside (isepamicin), excluding the initial use of glycopeptides \[[@B16][@B17]\]. The medical illness severity of MH patients and prolonged antibiotic use might be related to the relatively higher rate of ampicillin-resistant *E. faecium* and VREfm isolates in MH patients than in non-MH patients.

We found that ampicillin resistance is much higher in VSEfm MH than in VSEfm non-MH (97.6% vs 61.1%). We also found that ampicillin-resistant isolates harbored several virulence genes more frequently than ampicillin-susceptible isolates; *hyl* and *esp* were detected only in ampicillin-resistant isolates. Interestingly, there were also significant differences in ampicillin resistance rate among the non-MH isolates according to the type of ward: 94.1% in general ward (GW), 83.3% in intensive care unit (ICU), and 42.9% in emergency department (ER), respectively (*P*= 0.011). Similar trends were also observed for the prevalence of *hyl* (88.2% in GW, 83.3% in ICU, and 42.9% in ER, *P*=0.038) and *esp* (82.4% in GW, 75.0% in ICU, and 42.9% in ER, *P*=0.093). These differences may be due to previous exposure to antibiotics or to the bloodstream infection developed in a nosocomial or community setting. However, the scope of this study did not include investigating antibiotic exposure in the non-MH group.

pEF1071 was not detected in any of the ampicillin-susceptible isolates, although the result should be interpreted bearing in mind that the number of these isolates was low (n=7). pEF1071 encodes enterocins 1071A and 1071B \[[@B18]\]; as enterocins possess antimicrobial activity against closely related species, a producer strain would have a selective advantage over other strains in the same ecological niche \[[@B19]\].

It is interesting that *hyl*, *esp*, and *sgrA* were the virulence factors most frequently identified in isolates from MH patients, ampicillin-resistant isolates, and isolates harboring pEF1071. *esp* is known to be associated with resistance to ampicillin, imipenem, and ciprofloxacin \[[@B20][@B21]\]. A recent study observed high prevalence and persistence of ampicillin-resistant *E. faecium* colonization in patients receiving levofloxacin prophylaxis \[[@B22]\]. We hypothesize that the relatively high ampicillin resistance rate in *E. faecium* from MH patients in our hospital might be associated with ciprofloxacin prophylaxis administered to the MH patients. Further study is needed to determine whether there is any link between ampicillin resistance, virulence factors, and pEF1071.

Regardless of patient group, *hyl* and *sgrA* were more frequent in VREfm than in VSEfm. This might be due to co-localization of *vanA* and *hyl~Efm~* on the same plasmid \[[@B23]\]. *sgrA*, along with other virulence factors (*esp*, *hyl*, *acm*, *scm*, *ecbA*, *pilA*, and *pilB*), is known to play an important role in the emergence of ST78 VREfm in nosocomial infections \[[@B24]\]. Considering that *hyl*, *esp*, and *sgrA* are related to colonization of the gastrointestinal tract, primary surface attachment, and adhesion \[[@B25][@B26][@B27]\], these virulence factors could play a role in the development of enterococcal bacteremia originating from the gastrointestinal tracts of MH patients who frequently suffer from severe gut mucositis during prolonged, severe neutropenia. It is noteworthy that the prevalence of *hyl* and *esp* among the VREfm MH isolates increased from 49% to 88% and 68% to 86%, respectively, compared with a previous report from this BMT center \[[@B15]\]. *esp* plays a significant role in the prevalence of VREfm \[[@B27][@B28]\].

In terms of plasmid replicon typing, the majority of *E. faecium* isolates from MH patients harbored pLG1, which is a newly sequenced, 280-kb, conjugative plasmid encoding VanA-type glycopeptide resistance, macrolide resistance, carbon uptake-utilization genes, and putative virulence genes including *hyl* and a pilin gene cluster \[[@B23]\]. Further study is needed to investigate the role of pLG1 in the acquisition and transmission of vancomycin resistance in *E. faecium.*

In this study, we also analyzed the molecular epidemiology of *E. faecium* bacteremic isolates. Most *E. faecium* isolates (80.8%) belonged to clonal complex 17 (CC17) and comprised various STs, including ST17, ST230, ST192, ST78, and ST262. Previous studies have shown that CC17 can be resolved into three different lineages, originating from ST17, ST18, and ST78. While lineages 17 and 18 were predominant from 1990 to 2004, lineage 78 has become predominant since 2005 \[[@B29][@B30]\]. However, ST17 remained the most prevalent ST while ST230, a single locus variant of ST78, was predominant among MH patients at this hospital. In addition, five types of Tn*1546* were identified, of which two (II and IV) accounted for \>70% of the VREfm isolates. This finding indicates that both clonal spread and horizontal transfer played a role in the spread of vancomycin resistance within a hospital. In addition, diverse STs harbored Tn*1546* types II and IV. In cases of common STs, ST17 harbored Tn*1546* types I, II, IV, and V, and ST230 contained Tn*1546* types II and IV.

We wish to emphasize three findings. First, the rate of ampicillin resistance was higher in VSEfm MH than in VSEfm non-MH, and *hyl*, *esp*, and pEF1071 were detected only in isolates with ampicillin resistance. Based on these findings, we have decided to limit administration of ciprofloxacin prophylaxis to a select group of patients. Second, the prevalence of pLG1 was higher in *E. faecium* MH than in *E. faecium* non-MH, regardless of vancomycin resistance. Third, both clonal and horizontal transfers contributed to the transmission of VRE. Further study is, therefore, needed to investigate the genetic link between antimicrobial resistance and virulence factors.

In conclusion, antimicrobial resistance profiles and molecular characteristics, including the distribution of STs, virulence genes, and plasmids, were different and associated with the underlying diseases of patients within the same hospital. We presume that the prophylactic use of fluoroquinolone might have affected the antimicrobial resistance profiles and molecular characteristics of *E. faecium* and have thus decided to use fluoroquinolone more stringently in MH patients.
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###### *In vitro* resistance rate of *Enterococcus faecium* bacteremic isolates

![](alm-38-226-i001)

                                       VSEfm (N=60)   VREfm (N=60)                                            
  ------------------------------------ -------------- -------------- ----------- -------------- ------------- ----------
  Ampicillin                           41 (97.6%)     11 (61.1%)     **0.001**   42 (100%)      18 (100%)     \-
  High level gentamicin resistance     30 (71.4%)     7 (38.9%)      **0.023**   26 (61.9%)     11 (61.1%)    \> 0.999
  High level streptomycin resistance   10 (23.8%)     3 (16.7%)      0.736       5 (11.9%)      5 (27.8%)     0.256
  Vancomycin                           0 (0%)         0 (0%)         \-          42 (100%)      18 (100%)     \-
  Teicoplanin                          0 (0%)         0 (0%)         \-          41 (97.6%)     18 (100%)     0.303
  Linezolid                            0 (0%)         0 (0%)         \-          2 (4.8%)^\*^   0 (0%)        \> 0.999
  Quinupristin-dalfopristin            1 (2.4%)^†^    0 (0%)         \> 0.999    1 (2.4%)^†^    1 (5.6%)^†^   0.514
  Tigecycline                          0 (0%)         0 (0%)         \-          0 (0%)         0 (0%)        \-

Data are presented as n (%).

^\*^The minimal inhibitory concentrations (MICs) for two linezolid non-susceptible isolates were ≥8 mg/dL; ^†^The MICs for three quinupristin-dalfopristin non-susceptible isolates were 2 mg/dL.

Abbreviations: MH, hematologic patients; non-MH, non-hematologic patients; VREfm, vancomycin-resistant *E. faecium*; VSEfm, vancomycin-susceptible *E. faecium*.

###### Distribution of multilocus sequence types of *Enterococcus faecium* bacteremic isolates and Tn*1546* element characteristics

![](alm-38-226-i002)

  STs^\*^ (N)   VSEfm (N=60)   VREfm (N=60)                                                                                             
  ------------- -------------- -------------- ---------- ------------------------------------------ ----------------------------------- -----------
  ST17 (44)     18 (42.9%)     4 (22.2%)      0.155      11 (26.2%): I (1), II (3), IV (2), V (5)   11 (61.1%): I (4), II (5), IV (2)   **0.010**
  ST230 (23)    6 (14.3%)      2 (11.1%)      \> 0.999   14 (33.3%): II (10), IV (4)                1 (5.6%): II (1)                    **0.025**
  ST192 (17)    6 (14.3%)      3 (16.7%)      \> 0.999   6 (14.3%): II (2), IV (4)                  2 (11.1%): II (1), V (1)            \>0.999
  ST78 (8)      4 (9.5%)       1 (5.6%)       \> 0.999   2 (4.8%): II (1), III (1)                  1 (5.6%): I (1)                     \> 0.999
  ST262 (5)     1 (2.4%)       0 (0%)         \> 0.999   4 (9.5%): I (1), II (1), IV (2)            0 (0%)                              0.306
  ST18 (4)      3 (7.1%)       0 (0%)         0.547      0 (0%)                                     1 (5.6%): IV (1)                    0.300
  ST812 (4)     1 (2.4%)       3 (16.7%)      0.077      0 (0%)                                     0 (0%)                              \-
  ST64 (2)      1 (2.4%)       0 (0%)         \> 0.999   1 (2.4%): II (1)                           0 (0%)                              \> 0.999

Data are presented as n (%).

^\*^Other STs not presented in the table are singletons (ST66, ST80, ST117, ST178, ST202, ST203, ST233, ST389, ST7850, ST994, ST995, ST996, and ST997); ^†^Chi-square analysis was used to compare categorical variables. If any of the cells of a contingency table are below five, Fisher\'s exact test was used.

Abbreviations: MH, hematologic patients; non-MH, non-hematologic patients; VSEfm, vancomycin-susceptible *E. faecium*; VREfm, vancomycin-resistant *E. faecium*; Tn, transposon.

###### Virulence factors and plasmids observed in *E. faecium* isolates

![](alm-38-226-i003)

                         VSEfm (N = 60)   VREfm (N = 60)   *P*
  ---------------------- ---------------- ---------------- -----------
  Virulence factor^\*^                                     
   *hyl*                 **45 (76.7%)**   **55 (91.7%)**   **0.024**
   *esp*                 45 (75.0%)       52 (86.7%)       0.104
   *scm*                 45 (75.0%)       46 (76.7%)       \> 0.999
   *sgrA*                **51 (85.0%)**   **60 (100%)**    **0.003**
   *ecbA*                34 (56.7%)       43 (71.7%)       0.087
   *pilA*                41 (68.3%)       39 (65.0%)       0.699
   *pilB*                40 (66.7%)       41 (68.3%)       0.845
   *fms11*               49 (81.7%)       51 (85.0%)       0.654
   *fms14*               23 (38.3%)       19 (31.7%)       0.444
   *fms15*               40 (66.7%)       49 (81.7%)       0.061
  Plasmid                                                  
   pIP501                3 (5.0%)         6 (10.0%)        0.491
   pRE25                 48 (80.0%)       52 (86.7%)       0.327
   PEF1071               **42 (70.0%)**   **54 (90.0%)**   **0.006**
   pRI                   50 (83.3%)       56 (93.3%)       0.153
   pRUM                  12 (20.0%)       8 (13.3%)        0.327
   pEF418                45 (75.0%)       42 (70.0%)       0.540
   pMG1                  8 (13.3%)        16 (26.7%)       0.068
   pLG1                  44 (73.3%)       50 (83.3%)       0.184

^\*^Of the 15 virulence genes tested, several virulence genes were rarely identified or not found in the 120 *E. faecium* isolates; *cylA* (n=1), *gelE* (n=0), *asa1* (n=1), *agg* (n=0). *acm* was found in all of the isolates tested in this study (n=120).

Abbreviations: VSEfm, vancomycin-susceptible *E. faecium*; VREfm, vancomycin-resistant *E. faecium*.
